It is noteworthy that cut-offs for haemoglobin levels for clinical decision making (e.g. for clinical trial inclusion, transfusion, erythropoietin administration)29, 30, 31 are generally lower than the cut-off defining anaemia according to WHO. The gene discussed is EPO; the disease is anemia (phenotype).